Merck’s Gefapixant could become the first drug approved for Chronic Cough
ATS 2020 Virtual is happening from August 5 to August 10, and it is exciting to watch major Respiratory /Pulmonary Pharmaceutical companies and their key presentations.
Merck is worth mentioning here, as it is presenting key posters and studies on Gefapixant in Chronic Refractory Cough (CRC).
Gefapixant History:
In July 2016, Merck acquired MK-7264 from Afferent Pharmaceuticals by signing a definitive agreement to USD 1.25 billion.
Gefapixant Facts:
Gefapixant is a selective, non-narcotic, orally-administered P2X3 antagonist designed to target the mechanism by which certai...
